Released on 15/02/2018

Key Learning Points

  • Amaurosis fugax
  • Asymptomatic aortic aneurysms: management
  • CAP: empirical antibiotic therapy
  • CAP: markers of severity
  • GCA: aneurysm surveillance
  • GCA: immunomodulators
  • GCA: temporal artery biopsy
  • GCA: when to treat?
  • Giant cell arteritis (GCA)
  • Long-term glucocorticoids: osteoporosis prophylaxis
  • PET scan
  • Tocilizumab: details


1. PONTE C, RODRIGUES AF, O'NEILL L, LUQMANI RA. Giant cell arteritis: Current treatment and management World J Clin Cases [online] 2015 Jun 16, 3(6):484-494 [viewed 20 June 2017] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468893
2. NESS T, BLEY TA, SCHMIDT WA, LAMPRECHT P. The Diagnosis and Treatment of Giant Cell Arteritis Dtsch Arztebl Int [online] 2013 May 24, 110(21):376-386 [viewed 20 June 2017] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679627
3. AGGARWAL S, QAMAR A, SHARMA V, SHARMA A. Abdominal aortic aneurysm: A comprehensive review Exp Clin Cardiol [online] 2011 Spring, 16(1):11-15 [viewed 24 June 2017] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076160
4. BARRACLOUGH K, MALLEN CD, HELLIWELL T, HIDER SL, DASGUPTA B. Diagnosis and management of giant cell arteritis Br J Gen Pract [online] 2012 Jun, 62(599):329-330 [viewed 24 June 2017] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361116
5. KVICKSTRöM P, LINDBLOM B, BERGSTRöM G, ZETTERBERG M. Amaurosis fugax: risk factors and prevalence of significant carotid stenosis Clin Ophthalmol [online] 2016 Oct 31:2165-2170 [viewed 27 June 2017] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096748
6. FRASER JA, WEYAND CM, NEWMAN NJ, BIOUSSE V. The Treatment of Giant Cell Arteritis Rev Neurol Dis [online] 2008 Summer, 5(3):140-152 [viewed 27 June 2017] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3014829
7. ROBERTS J, CLIFFORD A. Update on the management of giant cell arteritis Ther Adv Chronic Dis [online] 2017 Mar 28, 8(4-5):69-79 [viewed 14 July 2017] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406009
8. VENKITESHWARAN A. Tocilizumab MAbs [online] 2009 Sep-Oct, 1(5):432-438 [viewed 15 July 2017] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759492
9. MBATA G, CHUKWUKA C, ONYEDUM C, ONWUBERE B, AGUWA E. The role of complications of community acquired pneumonia on the outcome of the illness: a prospective observational study in a tertiary institution in eastern Nigeria. Ann Med Health Sci Res [online] 2013 Jul, 3(3):365-9 [viewed 15 July 2017] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24116315
10. MANDELL LA, WUNDERINK RG, ANZUETO A, BARTLETT JG, CAMPBELL GD, DEAN NC, DOWELL SF, FILE TM JR, MUSHER DM, NIEDERMAN MS, TORRES A, WHITNEY CG, INFECTIOUS DISEASES SOCIETY OF AMERICA., AMERICAN THORACIC SOCIETY.. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis [online] 2007 Mar 1:S27-72 [viewed 15 July 2017] Available from: http://www.ncbi.nlm.nih.gov/pubmed/17278083
11. NESHER G, BREUER GS. Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update Rambam Maimonides Med J [online] 2016 Oct 31, 7(4):e0035 [viewed 20 July 2017] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101009